PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC)

This study assessed the grade 3/4 AE costs of N+I, N+C, and P+A from CheckMate-214 (CM-214), CheckMate-9ER (CM-9ER), KEYNOTE-426 (KN-426), respectively. Grade rates were obtained individual patient-level data CM-214 (restricted to median follow-up [RmFU], 13.1 months), CM-9ER (RmFU, 12.8 published results KN-426 trial (mFU, months). Per-patient all-cause treatment-related (TR) calculated for AEs reported in ≥20% patients. by multiplying incidence respective unit US 2017 Healthcare Cost Utilization Project database, inflated 2020 USD. N+I was associated with lowest total per-patient TRAE compared treatments. Total patients treated $6900, $10,892, $11,332, $741, $2722, $4440, Lower cost difference versus N+C largely driven differences hypertension ($193 vs $966 $1685), increased ALT ($553 $834 $1701), hypophosphatemia ($0 $2466 $721), AST ($412 $671 $1105), ($39 $768 $1490), ($389 $399 $1031), palmar-plantar erythrodysesthesia syndrome $486 $332), ($280 $266 $575), Patients aRCC had lower than those or P+A; P+A. These suggest that have a more favorable benefit-risk profile offer clinicians payers therapeutic option reduces clinical economic burden this population.